TG Therapeutics Inc (NASDAQ: TGTX) has a price-to-earnings ratio that is above its average at 1070.92x. The stock has a 36-month beta value of 2.32. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TGTX is 139.36M, and at present, short sellers hold a 24.53% of that float. On April 10, 2024, the average trading volume of TGTX was 4.25M shares.
TGTX) stock’s latest price update
The stock of TG Therapeutics Inc (NASDAQ: TGTX) has increased by 0.87 when compared to last closing price of 14.97. Despite this, the company has experienced a 4.57% gain in its stock price over the last five trading sessions. Seeking Alpha reported 2024-02-28 that TG Therapeutics, Inc. (TGTX) Q4 2023 Earnings Call Transcript
TGTX’s Market Performance
TG Therapeutics Inc (TGTX) has seen a 4.57% rise in stock performance for the week, with a -10.01% decline in the past month and a -29.11% plunge in the past quarter. The volatility ratio for the week is 3.64%, and the volatility levels for the past 30 days are at 3.99% for TGTX. The simple moving average for the last 20 days is -0.84% for TGTX stock, with a simple moving average of 6.49% for the last 200 days.
Analysts’ Opinion of TGTX
Many brokerage firms have already submitted their reports for TGTX stocks, with Goldman repeating the rating for TGTX by listing it as a “Neutral.” The predicted price for TGTX in the upcoming period, according to Goldman is $12 based on the research report published on August 02, 2023 of the previous year 2023.
Jefferies, on the other hand, stated in their research note that they expect to see TGTX reach a price target of $40, previously predicting the price at $55. The rating they have provided for TGTX stocks is “Buy” according to the report published on June 26th, 2023.
BofA Securities gave a rating of “Underperform” to TGTX, setting the target price at $5 in the report published on May 20th of the previous year.
TGTX Trading at -1.99% from the 50-Day Moving Average
After a stumble in the market that brought TGTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.67% of loss for the given period.
Volatility was left at 3.99%, however, over the last 30 days, the volatility rate increased by 3.64%, as shares sank -7.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.43% lower at present.
During the last 5 trading sessions, TGTX rose by +4.57%, which changed the moving average for the period of 200-days by -36.31% in comparison to the 20-day moving average, which settled at $15.16. In addition, TG Therapeutics Inc saw -11.59% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TGTX starting from Lonial Sagar, who sale 5,000 shares at the price of $15.94 back on Mar 13 ’24. After this action, Lonial Sagar now owns 108,878 shares of TG Therapeutics Inc, valued at $79,675 using the latest closing price.
Charney Laurence N, the Director of TG Therapeutics Inc, sale 22,000 shares at $15.97 during a trade that took place back on Mar 12 ’24, which means that Charney Laurence N is holding 215,229 shares at $351,340 based on the most recent closing price.
Stock Fundamentals for TGTX
Current profitability levels for the company are sitting at:
- 0.09 for the present operating margin
- 0.94 for the gross margin
The net margin for TG Therapeutics Inc stands at 0.06. The total capital return value is set at 0.07. Equity return is now at value 11.57, with 4.84 for asset returns.
Based on TG Therapeutics Inc (TGTX), the company’s capital structure generated 0.39 points at debt to capital in total, while cash flow to debt ratio is standing at -0.31. The debt to equity ratio resting at 0.63. The interest coverage ratio of the stock is 1.64.
Currently, EBITDA for the company is 21.06 million with net debt to EBITDA at 0.81. When we switch over and look at the enterprise to sales, we see a ratio of 10.06. The receivables turnover for the company is 4.57for trailing twelve months and the total asset turnover is 0.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.92.
Conclusion
To sum up, TG Therapeutics Inc (TGTX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
